CARVYKTI Sales Reach About $710 Million in Third Quarter of 2026
Key Facts
Legend Biotech reported that CARVYKTI generated net commercial sales of about $710 million in the quarter ended September 30, 2026, according to a filing with the U.S. Securities and Exchange Commission. The company said in the filing that the drug “generated net commercial sales of about $710 million during the quarter ended September 30, 2026.” The figure reflects sales recorded for the drug during the period, but is based on information provided by Janssen that Legend Biotech did not independently verify. The company therefore reported the value as approximate and explicitly linked it to the source of the information. The disclosure comes ahead of the third-quarter results announcement scheduled for November 10, after the sales figure had been tied to the quarter ended in September.
Earlier figures show sales continued to rise in 2026, while the reported annual growth rate declined from one quarter to the next. Net commercial sales were about $597 million in the first quarter, up 62% from the same period in 2025, according to a company filing. They then rose to about $657 million in the second quarter, up 50% year over year, according to another Legend filing. In the third quarter, they reached about $710 million, while the latest filing cited the sales figure but did not provide an annual growth rate for it in the available information. The reported value thus increased from about $657 million in the second quarter to about $710 million in the third, while the figures presented here do not allow an annual growth rate for the third quarter to be determined.
Expansion outside the United States was one factor in the growth recorded at the start of the year. In the first quarter, net commercial sales in the United States rose 36% year over year, while sales outside the country increased 222%, according to an investor-relations disclosure. The available third-quarter figure does not provide a comparable regional breakdown, so this comparison describes first-quarter performance and is not attributed to the more recent period. By the second quarter, the company said CARVYKTI was available at 348 sites worldwide and in 19 markets, with a launch in Ireland. These figures provide context on the drug’s expanding availability alongside the successive increases in quarterly sales.
On the management front, Ingrid Zhang took over as chief executive on September 15, 2026, after being appointed by Legend Biotech’s board, according to a separate company filing. She succeeded Alan Bash, who had served as interim chief executive since July 2026 and then returned to his role as president of CARVYKTI. The company said Zhang “is taking over from Alan Bash, who served as interim chief executive since July 2026.” Before joining Legend, Zhang was president of Novartis International from June 2024 to August 2026, according to the same filing. The management change put the company under the leadership of an executive with recent commercial experience, but it preceded the third-quarter results announcement and was not announced alongside it.
In May, Legend said that available cash and the operating cash flows it expected to generate would, in its assessment at the time, provide sufficient resources to meet operating needs and repay loans for at least 12 months. The company tied that assessment to its position as of March 31, 2026, according to an investor-relations disclosure. The filing does not state the value of cash and deposit balances at the end of September, so it is not a third-quarter liquidity figure. It also reflects an earlier company estimate of coverage for operating needs and loan repayments, not an updated statement about those needs after September ended. The estimate provides earlier financial context for the drug’s commercial performance without replacing more recent cash data.
Legend Biotech shares, listed under the ticker LEGN, closed at $24.29 on November 9, 2026, according to EL7 data. That value is for the trading session before the third-quarter results event and does not by itself show the share’s direction during the session or its response to the results. The company had scheduled the results event for November 10 at 8:00 a.m. U.S. Eastern Time, according to its investor-relations page. The company also announced in early November that it would present CARVYKTI and its next-generation cell therapy programs at the 2026 American Society of Hematology meeting. The meeting announcement places the next therapeutic developments on the company’s agenda after the results event.